Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses the struggle with diffuse hair thinning and the effectiveness of treatments like finasteride, minoxidil, and RU58841. Users share experiences of hair thickening and shedding stopping with these treatments, but results vary and some are skeptical.

OrganTech is working on regenerating hair and teeth, with positive results in mice, but skepticism remains about progress for humans. Users express frustration over the lack of advancements in human hair loss treatments, despite ongoing research and trials.

The user has been using 1mg finasteride daily, minoxidil foam once or twice a day, and Nizoral shampoo 3-4 times weekly for 8 months, noticing some shedding but not much growth. Others suggest patience, microneedling, or additional treatments like dutasteride, PRP, or exosomes for better results.

The conversation is about using Xeljanz for hair regrowth in individuals with LPP. The user is seeking experiences and expectations from others who have tried this treatment.

The user is experiencing hair regrowth after 8 months using 1mg finasteride three times a week, topical minoxidil twice a day, and recently started microneedling with a 1mm needle. Optimal results are expected after one year.

Switching from finasteride to dutasteride may stop further hair loss, but noticeable thickness gains can take over six months. Minoxidil can increase hair density, and microneedling may enhance its effectiveness.

Eirion Therapeutics is recruiting for phase 1 of ET-02 in Texas, which showed promising hair growth results in non-clinical studies. ET-02 demonstrated significantly more hair growth compared to Minoxidil.

Brian Dye's theory links skeletal malocclusion type II to hair loss, suggesting it's a blood flow issue. Treatments mentioned include minoxidil, finasteride, and anti-inflammatory drugs like benaxoprofen.

The conversation discusses a patent for using topical resveratrol and melatonin to treat androgenetic alopecia (AGA) and also mentions interest in topical sulforaphane as a treatment.

Kx-826 at 0.5% shows limited effectiveness for hair loss, while 1% is more promising but expensive. RU58841 is considered a more feasible option until 1% kx-826 becomes affordable.